Soluble CD95 (Fas/APO-1) in malignant glioma: (No) implications for CD95-based immunotherapy?

Journal of Neuro-Oncology

Volumn 40, Issue 3, 1998, Pages 233-235

  Streffer, Johannes R ^a   Schuster, Monika ^a   Zipp, Frauke ^a   Weller, Michael ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Apoptosis; Brain; CD95; CSF; Glioma

Indexed keywords

FAS ANTIGEN; MESSENGER RNA;

ALTERNATIVE RNA SPLICING; ARTICLE; BIOASSAY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLIOBLASTOMA; HUMAN; HUMAN CELL; LUMBAR DISK HERNIA; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; TUMOR CELL LINE;

EID: 0032425689     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006173019048     Document Type: Article

References (15)

1. Ogasawara J, Walanahe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S: Lethal effect of the anti-Fas antibody in mice. Nature 364: 806-809, 1993
2. Weller M, Kleihues P, Dichgans J, Ohgaki H: CD95 ligand: lethal weapon against malignant glioma? Brain Pathol 8: 285-293, 1998
3. Becher B, D'Souza SD, Troutt AB, Antel JP: Fas expression on human fetal astrocytes without susceptibility to Fas-mediated cytotoxicity. Neuroscience 84: 627-634, 1998
4. Leithäuser F, Dhein J, Mechtersheimer G, Koretz K, Brüderlein S, Henne C, Schmidt A, Debatin KM, Krammer PH, Möller P: Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor superfamily, in normal and neoplastic cells. Lab Invest 69: 415-429, 1993
5. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PI, Mountz JD: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263: 1759-1762, 1994
6. Zipp F, Weller M, Calabresi PA, Frank JA, Bash CN, Dichgans J, McFarland HF, Martin R: Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing remitting multiple sclerosis. Ann Neurol 43: 116-120, 1998
7. Zipp F, Ötzelberger K, Dichgans J, Martin R, Weller M: Serum CD95 of multiple sclerosis patients protects from CD95-mediated apoptosis. J Neuroimmunol 86:151-154, 1998
8. Owen-Schaub LB, Angelo LS, Radinsky R, Ware CF, Gesner TG, Bartos DP: Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis? Cancer Lett 94: 1-8, 1995
9. Midis GP, Shen Y, Owen-Schaub LB: Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res 56: 3870-3874, 1996
10. Weller M, Malipicro U, Rensing-Ehl A, Barr P, Fontana A: Fas/APO-1 gene transfer for human malignant glioma. Cancer Res 55: 2936-2944, 1995
11. Tachibana O, Nakazawa H, Lampe J, Watanabc K, Kleihues P, Ohgaki H: Expression of Fas/APO-1 during the progression of astrocytomas. Cancer Res 55: 5528-5530, 1995
12. Roth W, Fontana A, Trepel M, Dichgans J, Reed JC, Weller M. Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics. Cancer Immunol Immunother 44: 55-63, 1997
13. Saas P, Walker PR, Hahne M, Quiquerez AL, Schnuriger V, Perrin G, French L, van Meir EG, de Tribolct N, Tschopp J, Dietrich PY. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest 9: 1173-1178, 1997
14. Gratas C, Tohma Y, Van Meir EG, Klein M, Tenan M, Ishii N, Tachibana O, Kleihues P, Ohgaki H. Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol 7: 863-869, 1997
15. Weller M, Weinstock C, Will C, Wagenknecht B, Dichgans J, Lang F, Gulbins E. CD95-dependent T-cell killing by glioma cells expressing CD95 ligand: more on tumor escape, the CD95 counterattack, and the immune privilege of the brain. Cell Physiol Biochem 7: 282-288, 1997